Kymera reports positive KT-579 Phase 1 data, updates KT-621 and cash runway

Kymera Therapeutics announced on October 29, 2026 financial results for the third quarter ended September 30, 2026 along with positive results from the Phase 1 healthy volunteer trial of KT-579, its IRF5 degrader. The company announced positive results from the completed first-in-human KT-579 Phase 1 healthy volunteer trial, with results meeting or exceeding study objectives and establishing strong proof of mechanism.¹

In the multiple ascending dose portion of the trial, KT-579 demonstrated deep, sustained IRF5 degradation in blood, with at least 90% median degradation across multiple dose levels with saturation of degradation by dose level 3, and similar reductions in IRF5 levels were observed in skin.¹ Using the median of all MAD dose cohorts, the inflammatory cytokine and interferon analysis showed inhibition of 88% of TNFα, 87% of IL-12/23p40, 94% of IL-1β, and 98% of IFNβ at Day 14.¹ On safety, the safety profile of KT-579 was comparable to placebo, with no serious or severe adverse events and none leading to discontinuation, very few mild treatment-related adverse events with no dose-dependent pattern, and no clinically relevant changes in vital signs, labs or ECGs.¹

The KT-579 LUMORA Phase 1b trial in lupus patients is planned to start by early 2027, a randomized, double-blind, placebo-controlled study testing KT-579 in approximately 30 adult patients with systemic lupus erythematosus dosed over 16 weeks, aimed at demonstrating biomarker modulation and exploring clinical benefit.¹

For the STAT6 program, the last patient completed the week 16 visit in the KT-621 BROADEN2 Phase 2b atopic dermatitis trial in October 2026, with topline data expected by year-end 2026 and the first Phase 3 AD trial expected to start by mid-2027 pending regulatory discussions.¹ The KT-621 BREADTH Phase 2b asthma trial continues to enroll, with topline data expected in late 2027.¹

On partnered programs, the first-in-human Phase 1 trial of KT-485 (SAR447971) in healthy volunteers and hidradenitis suppurativa patients is ongoing, with Sanofi leading development, regulatory and commercial efforts.¹ Gilead Sciences is advancing KT-200, a CDK2 molecular glue degrader discovered by Kymera and exclusively licensed to Gilead, in IND-enabling studies to support a 2027 IND filing.¹

As of September 30, 2026, Kymera had $1.6 billion in cash, cash equivalents and investments, which the company said provides a cash runway into 2029.¹